Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 5 Changes of MICB, UBLP1, and splenic volume before and after (S)-ketamine administration between the study group and the control group

From: Correlations between major depressive disorder, splenic morphology, and immune function

Indexes

Baseline

4 weeks

t

P

MICB (pg/ml)

Study Group (n = 40)

166.93 ± 12.17

138.63 ± 26.15

6.742

 < 0.001

Control Group (n = 40)

162.95 ± 19.83

163.68 ± 9.43

- 0.276

0.784

UBLP1 (ng/ml)

Study Group (n = 40)

115.91 ± 6.48

110.26 ± 8.60

4.201

 < 0.001

Control Group (n = 40)

114.55 ± 6.17

112.50 ± 9.21

1.108

0.275

Splenic volume

(cm3)

Study Group (n = 40)

198.04 ± 71.40

173.83 ± 55.32

2.729

0.009

Control Group (n = 40)

200.01 ± 67.03

194.52 ± 63.48

0.669

0.508

  1. Note: Both the study group and the control group were included in the MDD group, with (S)-ketamine as the intervention factor; the unit of splenic volume is cubic centimeter, cm3
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us